Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Pockets $22M in Private Share Placement

NEW YORK, Dec. 26 - Visible Genetics has secured $22 million in a private placement of some 2.6 million common shares, the company said on Wednesday. The funds will be used for general working capital purposes, Visible Genetics said.


The per-share price of $8.34 represents a 16-percent discount to the average closing price over ten days leading up to the offering.


Last month, Visible Genetics, based in Toronto, blamed a dip in sales and services on a slight decrease in third-quarter revenues, which slipped to $2.9 million from $3.0 million in the year-ago quarter. Expenses in the quarter, however, rose to $12.6 million from $10.3 million year over year.


Also for that period, the company posted net losses attributable to common shareholders of $12.6 million, or 76 cents a share, compared net losses of $9.7 million, or 63 cents a share, reported in the same period one year ago.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.